We, the investigators at University of Washington, plan on evaluating the effect of open
label Asacol at a dose of 4.8 grams/day divided BID (twice per day) or TID (three times per
day) on its ability to induce remission in patients with mild to moderately active ulcerative
colitis. We hypothesize that both regimens will have the same efficacy and no difference in
side effects.